Versuchen GOLD - Frei

State DCs to take action not implementing Sch M

Chronicle Pharmabiz

|

November 13, 2025

Action will be initiated right now for those units who have not applied for the extension, as the revised Schedule M is already applicable for such units,” said Dr Rajeev Singh Raghuvanshi, DCGI.

The decision is expected to impact the existence of thousands of small and medium units who have not applied for the extension, and have been waiting for the centre to provide further relaxation of timeframe. Some of the units have already decided not to go for the revised Schedule M compliance and either shut down the unit or sell it to parties who are interested in upgrading the facility.

FURTHER EXTENSION RULED OUT

“In case any manufacturing unit is found noncomplying to the requirements of revised Schedule M during inspections, strict action shall be initiated against such units as per the provisions of Drugs and Cosmetics Act and Rules thereunder,” added the central drug regulator.

The State and UT drug regulators have to submit a monthly report to the Centre with details of inspections and observations made, and the actions taken pursuant to such inspections.

“This may be treated as Top Priority and compliance is required to be ensured strictly,” added the DCGI.

According to reports, Himachal Drug Manufacturers Association president Dr Rajesh Gupta has recently said that though the micro, small and medium enterprises are trying to comply with the revised standards, considering the investments required, at least 4,000-5,000 units might be forced to shut down and this may trigger shortage of critical drugs in the domestic market. Suspension: permanently prevent caking / sedimentation

Toothpaste: prevents drying up / water separation while giving fine texture

Emulsion: prevents emulsion breaking while giving fine texture

Tablets: Improves dissolution, binding & flow properties Our Bureau, New Delhi

WEITERE GESCHICHTEN VON Chronicle Pharmabiz

Chronicle Pharmabiz

Chronicle Pharmabiz

Home-grown CAR-T cell therapies gaining ground

INDIAN biotech and pharmaceutical companies are actively working on innovative solutions to make CART cell therapy both accessible and cost-effective.

time to read

4 mins

November 27, 2025

Chronicle Pharmabiz

NPPA extends price fixation on orthopaedic implants for 1 year

IN a move that will disappoint the industry, the National Pharmaceutical Pricing Authority (NPPA) has extended the ceiling price fixation it imposed on orthopaedic knee implants for knee replacement system for one more year.

time to read

1 mins

November 27, 2025

Chronicle Pharmabiz

FICCI envisages it's Smart AAMs to boost healthcare

In line with the Central Government's vision of comprehensive primary healthcare, FICCI Swasth Bharat Task Force has undertaken a transformative initiative titled 'Smart Ayushman Arogya Mandirs-AAMs' (earlier called Health & Wellness Centres) aimed at strengthening the primary healthcare delivery system across India.

time to read

1 min

November 27, 2025

Chronicle Pharmabiz

DoP asked to bring policy for affordable drug pricing

THE Parliamentary Panel on Chemicals and Fertilisers has recommended to the Department of Pharmaceutical (DoP) to take steps to come out with a pharmaceutical policy with thrust to provide both scheduled and nonscheduled formulations at affordable prices.

time to read

1 mins

November 27, 2025

Chronicle Pharmabiz

Ramaiah emphasises need for bone health and osteoporosis diagnosis

RAMAIAH Memorial Hospital (RMH), a multi-superspecialty quaternary care hospitals emphasises on bone health and osteoporosis diagnosis. It calls for timely screening and diagnosis through the new and advanced DXA scanner with superior and accurate test results.

time to read

2 mins

November 27, 2025

Chronicle Pharmabiz

Nathealth calls for action in 2026-27 Union Budget

NATHEALTH has submitted its budget 2026-27 recommendations to the Union government, outlining a roadmap to strengthen healthcare delivery, foster innovation, and expand insurance and preventive coverage.

time to read

1 mins

November 27, 2025

Chronicle Pharmabiz

Hotspots & growth opportunities in biomanufacturing

THE Indian bioeconomy has grown from US$ 10 billion in 2014 to US$ 165.7 billion in 2024, and is likely reach US$ 300 billion by 2030.

time to read

3 mins

November 27, 2025

Chronicle Pharmabiz

Omega Hospitals acquires Cytecare Hospitals

Morgan Stanley PE backed Hyderabad-based Omega Hospitals has acquired Cytecare Hospitals, a leading cancer care hospital in Bengaluru.

time to read

2 mins

November 27, 2025

Chronicle Pharmabiz

Devices sector hails withdrawal of QCOs

THE medical devices manufacturers industry in the country has welcomed the Central government's decision to withdraw multiple Quality Control Orders (QCOs) imposed on essential raw materials across various industries, including the medical devices sector.

time to read

1 min

November 27, 2025

Chronicle Pharmabiz

'There is urgent need for tech-focused regulatory approach for med devices'

THE Indian healthcare industry has evolved at a breakneck pace, but its regulatory framework has struggled to keep up to its speed of development.

time to read

2 mins

November 27, 2025

Listen

Translate

Share

-
+

Change font size